BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
BIOMERICA INC
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026
$1.76−0.09 (-4.86%)
Close on Oct 19, 2026
- Market cap
- $5.80M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.22 (−40.94%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
BIOMERICA INC saw revenue fall 11.2% to $4.34M over the twelve months to Aug 31, 2026.
Revenue
$4.34M
-11.2% vs. a year earlier
Operating income
-$5.43M
TTM Q1 2027
EPS, diluted
-$1.63
TTM Q1 2027
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Aug 31, 2026
Valuation
- Market cap
- $5.80M
- P/E ratio
- –
- Price to sales
- 1.34
- Price to book
- 1.59
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $4.34M
- Net income
- -$5.01M
- EPS, diluted
- -$1.63
- Book value per share
- $1.11
- Diluted shares
- 3M
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
$4.34M-11.2% YoY
Gross profit
$39.00K-93.9% YoY
Operating income
-$5.43M
Net income
-$5.01M
EPS, diluted
-$1.63
Free cash flow
–
Reported periodTrailing twelve months